Achieve Life Sciences, Inc. (ACHV) Stock Price

ACHVStock

$6.38+107.14%52W

Market Cap$657.79M

P/E—

PEG Ratio17.68

Div yield—

Beta2.46

ACHV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)66.83%

Price vs S&P 500 (4W)-19.42%

PEG Ratio17.68

VGM Score36.21

Book Value / Share (Quarterly)$0.20

P/TBV (Annual)12.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-44.67%

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)16.44%

Net Profit Margin (TTM)-94.67%

EPS (TTM)$-1.55

10-Day Avg Trading Volume1.33M

EPS Excl Extra (TTM)$-1.55

Revenue Growth (5Y)-1.65%

EPS (Annual)$-1.25

ROI (Annual)-150.10%

Gross Margin (Annual)-98.76%

Net Profit Margin (5Y Avg)-159.73%

Cash / Share (Quarterly)$1.82

ROA (Last FY)-130.77%

Revenue Growth TTM (YoY)-89.25%

EBITD / Share (TTM)$-0.93

ROE (5Y Avg)-222.50%

Operating Margin (TTM)-106.51%

Cash Flow / Share (Annual)$-0.93

P/B Ratio61.48x

P/B Ratio (Quarterly)14.66x

Net Income / Employee (Annual)$-1,951,700

EV / Revenue (TTM)34.99x

Net Interest Coverage (TTM)-88.50x

ROA (TTM)-143.73%

EPS Incl Extra (Annual)$-1.25

Current Ratio (Annual)4.39x

Quick Ratio (Quarterly)0.95x

3-Month Avg Trading Volume1.76M

52-Week Price Return107.14%

Revenue / Employee (TTM)$75,700

Tangible BV / Share (Quarterly)$0.19

P/S Ratio (Annual)129.75x

Asset Turnover (Annual)0.18x

52-Week High$8.64

Operating Margin (5Y Avg)-175.65%

EPS Excl Extra (Annual)$-1.25

CapEx CAGR (5Y)-31.57%

Tangible BV CAGR (5Y)5.41%

26-Week Price Return76.73%

Quick Ratio (Annual)4.01x

13-Week Price Return1.75%

Total Debt / Equity (Annual)0.69x

Current Ratio (Quarterly)0.95x

Enterprise Value$623.47M

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)-49.48%

Revenue / Employee (Annual)$180,700

Pretax Margin (Annual)-397.83%

Cash / Share (Annual)$0.68

3-Month Return Std Dev57.79%

Gross Margin (5Y Avg)-120.50%

Net Income / Employee (TTM)$-4,072,900

ROE (Last FY)-253.96%

Net Interest Coverage (Annual)-95.08x

EPS Basic Excl Extra (Annual)$-1.25

P/FCF (TTM)108.52x

Receivables Turnover (TTM)20.24x

Total Debt / Equity (Quarterly)1.40x

EPS Incl Extra (TTM)$-1.55

Receivables Turnover (Annual)20.65x

ROI (TTM)-132.45%

P/S Ratio (TTM)36.84x

Pretax Margin (5Y Avg)-159.73%

Revenue / Share (Annual)$506.00

Tangible BV / Share (Annual)$0.39

Price vs S&P 500 (52W)91.61%

Year-to-Date Return28.37%

5-Day Price Return-9.63%

EPS Normalized (Annual)$-1.25

ROA (5Y Avg)-119.77%

Net Profit Margin (Annual)-397.83%

Month-to-Date Return-21.14%

EBITD / Share (Annual)$-1.26

Operating Margin (Annual)-418.77%

LT Debt / Equity (Annual)0.52x

ROI (5Y Avg)-114.02%

LT Debt / Equity (Quarterly)0.87x

EPS Basic Excl Extra (TTM)$-1.55

P/TBV (Quarterly)15.68x

P/B Ratio (Annual)12.30x

Pretax Margin (TTM)-94.67%

Book Value / Share (Annual)$0.40

Price vs S&P 500 (13W)-0.93%

Beta2.46x

P/FCF (Annual)18.83x

Revenue / Share (TTM)$212.00

ROE (TTM)-193.49%

52-Week Low$2.62

vGradeF

gGradeF

mGradeB

vgmGradeD

ACHV Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.16	-$0.80	-400.00%(-$0.64)
Q1 2026	May 12, 2026	-$0.30	-$0.19	+36.36%(+$0.11)
Q4 2025	Mar 24, 2026	-$0.28	-$0.28	-1.20%(-$0.00)
Q3 2025	Nov 6, 2025	-$0.26	-$0.28	-7.69%(-$0.02)
Q2 2025	Aug 7, 2025	-$0.35	-$0.37	-4.23%(-$0.02)

ACHV Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.07

4.13

4.12

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About Achieve Life Sciences, Inc.

Achieve Life Sciences is a specialty pharmaceutical company developing and commercializing cytisinicline, an established smoking cessation treatment approved in Central and Eastern Europe. The company aims to expand cytisinicline's availability as a treatment for nicotine addiction and address the global smoking health epidemic.